Apr 30, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 1: Appropriate Identification of Candidates for and Practical Implementation of Oral Selective Estrogen Receptor Degraders (SERDs) for Progressive HR-Positive,...

Apr 30, 2026

Year in Review: Clinical Investigator Perspectives on the Most Relevant New Datasets and Advances in Oral SERDs for Breast Cancer | Faculty Presentation 2: Future Directions in the Use of Oral SERDs for HR-Positive, HER2-Negative BC — Erica Mayer, MD, MPH, FASCO

CME information and select...

Apr 30, 2026

Featuring perspectives from Dr Aditya Bardia and Dr Erica Mayer, including the following topics:

• Introduction: How Selective Estrogen Receptor Degraders (SERDs) Work (0:00)
• Second-Line Treatment for Metastatic Breast Cancer (16:01)
• First-Line Therapy for Metastatic Disease (33:19)
• Adjuvant Therapy (35:26)
• Toxicity,...

Apr 16, 2026

Featuring an interview with Dr Seth Wander, including the following topics:

• Deciding between liquid and tissue biopsy; role of epigenetics in oncogenic events (0:00)
• Potential role of thymidine kinase testing in monitoring response to therapy (4:56)
• Interpretation of next-generation sequencing testing; use of targeted...

Apr 16, 2026

Featuring a slide presentation and related discussion from Dr Seth Wander, including the following topics:

• Biological impact of clinically relevant biomarkers (eg, ESR1 mutations, PIK3CA/AKT1/PTEN alterations) (0:00)
• Methodologies for biomarker assessment in clinical practice: Tissue versus liquid biopsy...